| Drug NDC: | 43742-1394 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Energize |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Sarcolacticum Acidum, Viscum Album, Iodium, Fucus Vesiculosus, Galium Aparine, Thyroidinum (suis), Dhea (dehydroepiandrosterone), Phenyl Isothiocyanate, Tyramine, Adenosinum Triphosphoricum Dinatrum, Alpha-ketoglutaricum Acidum, Fumaricum Acidum, Malic Acidum, Colchicum Autumnale, Conium Maculatum, Natrum Oxalaceticum, Funiculus Umbilicalis Suis, Hepar Suis, Medulla Ossis Suis, Pineal Gland (suis), Spleen (suis), Thymus (suis), Calcarea Fluorica, Pulsatilla (vulgaris), Spongia Tosta, Cortisone Aceticum |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Deseret Biologicals |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Tablet |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ADENOSINE TRIPHOSPHATE DISODIUM - 7 [hp_X]/1 ANEMONE PULSATILLA - 12 [hp_X]/1 CALCIUM FLUORIDE - 12 [hp_X]/1 COLCHICUM AUTUMNALE BULB - 8 [hp_X]/1 CONIUM MACULATUM FLOWERING TOP - 8 [hp_X]/1 CORTISONE ACETATE - 30 [hp_X]/1 ESCHERICHIA COLI - 30 [hp_C]/1 FUCUS VESICULOSUS - 6 [hp_X]/1 FUMARIC ACID - 7 [hp_X]/1 GALIUM APARINE - 6 [hp_X]/1 Load more... IODINE - 3 [hp_X]/1 LACTIC ACID, L- - 3 [hp_X]/1 LIOTHYRONINE - 15 [hp_C]/1 MALIC ACID - 7 [hp_X]/1 MERCURIC CHLORIDE - 60 [hp_X]/1 OXOGLURIC ACID - 7 [hp_X]/1 PHENYL ISOTHIOCYANATE - 6 [hp_X]/1 PORK LIVER - 8 [hp_X]/1 PRASTERONE - 6 [hp_X]/1 SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR ENTERITIDIS - 30 [hp_C]/1 SODIUM DIETHYL OXALACETATE - 8 [hp_X]/1 SPONGIA OFFICINALIS SKELETON, ROASTED - 12 [hp_X]/1 SUS SCROFA BONE MARROW - 8 [hp_X]/1 SUS SCROFA PINEAL GLAND - 8 [hp_X]/1 SUS SCROFA SPLEEN - 8 [hp_X]/1 SUS SCROFA THYMUS - 8 [hp_X]/1 SUS SCROFA THYROID - 6 [hp_X]/1 SUS SCROFA UMBILICAL CORD - 8 [hp_X]/1 TYRAMINE - 6 [hp_X]/1 VISCUM ALBUM FRUITING TOP - 3 [hp_X]/1 |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 26 Sep, 2018 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 19 Nov, 2023 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 05 May, 2026 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Deseret Biologicals |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000175946 M0021977 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 5L51B4DR1G I76KB35JEV O3B55K4YKI 993QHL78E6 Q28R5GF371 883WKN7W8X 514B9K0L10 535G2ABX9M 88XHZ13131 Z4B6561488 Load more... 9679TC07X4 F9S9FFU82N 06LU7C9H1V 817L1N4CKP 53GH7MZT1R 8ID597Z82X 0D58F84LSU 6EC706HI7F 459AG36T1B Y3V16D4PV4 6CA025Y4FG 1PIP394IID VP2CN2G7Y8 050QZ2EDK7 92AMN5J79Y 7B69B0BD62 6RV024OAUQ 118OYG6W3H X8ZC7V0OX3 BK9092J5MP |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | l-Triiodothyronine [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class CS: | Triiodothyronine [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Corticosteroid Hormone Receptor Agonists [MoA] Corticosteroid [EPC] Triiodothyronine [CS] l-Triiodothyronine [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 43742-1394-1 | 90 TABLET in 1 BOTTLE (43742-1394-1) | 26 Sep, 2018 | 19 Nov, 2023 | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.